Modernas CFO on the $25 billion innovation plan to work past the post-COVID slump – Fortune

Good morning.

Moderna is repositioning itself in the biotechnology space by betting on new innovation based on its mRNA platform. Moderna CFO Jamey Mock will play a major role in mitigating risk in these big investments as demand for the companys only marketable product at this timethe COVID-19 vaccinelags.

Modernas total revenue for Q3 2023 was $1.8 billion, compared to $3.4 billion in the same period in 2022, the company reported on Thursday. This is mainly due to a decrease in sales of the COVID-19 vaccine. Net product sales for the third quarter of 2023 were $1.8 billion, a decrease of 44% compared to the same period in 2022.

The companys 2023 sales guidance has been revised to at least $6 billion overall (previously $6 to $8 billion), and at least $2 billion from the U.S. (previously $2 to $4 billion).

After looking through the month of October, it appears as though vaccinations are really following a trend consistent with last year, which would be on the lower end, Mock says.

The soft demand for COVID-related products also resulted in a drop in sales for the companys competitor, Pfizer.

Moderna has taken steps like reducing manufacturing capacity to make sure the COVID franchise is a continuous and increasing source of income and cash generation next year, Mock says.

But hes seeing these headwinds as a breeding ground for innovation.

Theres a true organic growth opportunity here, Mock says. We still believe that we will launch 15 products by 2028. These will include respiratory, oncology, rare disease and latent disease products, he says.

Among those is the experimental vaccine against respiratory syncytial virus (RSV). Moderna filed with regulators in July for full approval of the one syringe shot for adults ages 60 and older.

Moderna plans on investing approximately $25 billion in research and development (R&D) from 2024 through 2028. This is all geared toward long-term value creation for the company, Mock says.

To support innovation and growth, his number one priority is understanding how much the company can afford to spend, Mock says.

Our view is that were fortunate to have a fair amount of capital right now, he explains. At the end of the third quarter, we have $13 billion in cash. In 2024, our sales will go down to what we think is about $4 billion. So we will most likely make a loss in the year 2024 and deplete some of that capital. We actually think thats the right thing to do. Now, you cant do it forever. But the company is committing to break even by the end of 2026, he says.

Another priority is assessing where to spend, he says. For example, Moderna has de-risked infectious disease vaccines due to prior success with COVID, and now with RSV, he says. So its easier to invest there from a probability of success perspective, Mock says.

He continues, We also look at the duration and time to revenue. The way we can innovate more is to actually get more sales to be able to afford more capital to reinvest back in the business. And then theres diversification and risk management, he says. We dont want to put all of our eggs into a respiratory vaccine basket, thats why you see us investing in oncology and latent disease and rare disease, Mock says.

And his third priority is helping with execution, especially in regard to the remaining manufacturing facilities, Mock says. So thats investing in it, making sure that it has a lot of automation, making sure that its super efficient. And when these products are ready to be sold, we have a reliable source of supply.

He adds, finance, communications, and HR also need to support our frontline and make sure that we can do that in the most efficient way.

Have a good weekend.

Sheryl Estrada sheryl.estrada@fortune.com

Some notable moves this week

Jamie Millerwas named EVP and CFO ofPayPal (Nasdaq: PYPL), effective Nov. 6. Miller will succeed Gabrielle Rabinovitch, who is currently acting CFO.Miller most recently served as global CFO of EY, having joined to lead the separation and IPO of its strategy, tax, and consulting business. Between June 2021 and January 2023, she served as CFO of Cargill.

Tony Skiadas was promoted to CFO at Verizon Communications, Reuters reported. Skiadas, who has a 27-year tenure at Verizon, had been serving as the interimCFOsince March 2023.

Troy Ignelzi was named CFO at Rapport Therapeutics, Inc., a clinical-stage biotechnology company, effective Nov. 1. Ignelzi joins Rapport with nearly two decades of financial leadership experience. Most recently, he was CFO at Karuna Therapeutics. Before Karuna, Ignelzi served as CFO at Juventas Therapeutics and scPharmaceuticals.

Beth Howewas named EVPand CFO atSiTime Corporation(Nasdaq: SITM), the precision timing company, effective Nov. 8. Art Chadwick has decided to step down as CFO and retire, effective Nov. 7. During her 17 years at HP Inc., Howe held numerous finance roles, most recently serving as HPs chief audit executive.

Holly Agliowas named CFO atMarchex, Inc.(Nasdaq: MCHX), a conversation intelligence company.Most recently, Aglio was CFO and a member of the board of directors of NetCentrics and led its 2021 acquisition by Cerberus Capital Management.

Brian Unruhwas named CFO and a member of the executive team atABBYY, an intelligent automation company. Unruh brings 20 years of experience serving in executive management positions at public and private equity-backed software and platform-as-a-service companies.

Raime Leebywas named CFO atDHI Group, Inc.(NYSE: DHX), a provider of AI-powered career marketplaces. Leebybrings over 23 years of financial experience. Before joining DHI, she served as chief strategy officer and interim CFO at US Med-Equip, a company that provides medical equipment and solutions to hospitals.

Andrew Jacksonwas appointed CFO atCalidi Biotherapeutics, Inc.(NYSEAM: CLDI), a clinical-stage biotechnology company. Jackson has over 25 years of corporate finance experience. He most recently served asCFO of Eterna Therapeutics Inc. Before that, he served as CFO at Ra Medical Systems for over four years.

E-TRADE from Morgan Stanley has released itsmonthly sector data on net buys and sells on the platform.

With the S&P 500 declining for a third-straight month in October, E-TRADE clients shifted somewhat into single stock selectionpotentially taking advantage of depressed pricing, Chris Larkin, managing director of trading and investing at E-TRADE from Morgan Stanley, said in an emailed statement. Amid a relatively strong earnings season, traders concentrated some of their buying in AMZN, as the company beat expectations. And, as geopolitical tensions deepen, we saw traders eye the industrials sector with particular interest in Boeing. On the flip side, no big surprises on the net selling front, as traders unloaded consumer staples with the economy humming along and real estate with interest rates remaining high.

Here are a fewFortuneweekend reads:

Tim Cook keeps giving the same answer about Apples generative AI plans, and its falling flat with investors by Rachyl Jones

Disney is buying Comcasts stake in streaming service Hulubut the $8.6 billion price tag is just the beginning and could go much higher, by Christiaan Hetzner

CEO of Ozempic prescription startup Calibrate steps down as investors eye rapid down-sizing of consumer business by Jessica Mathews

Starbucks CEO reveals 3 secrets in his daily routine that helped him beat executive burnout by Alexa Mikhail

Sam Bankman-Fried perpetrated one of the biggest financial frauds in American historya multibillion-dollar scheme designed to make him the king of crypto.But heres the thing: The cryptocurrency industry might be new, the players like Sam Bankman-Fried might be new, but this kind of fraud, this kind of corruption, is as old as time. And we have no patience for it.

U.S. AttorneyDamian Williamssaid at a Thursday night press conference after a12-person jury found Sam Bankman-Fried guilty of seven counts, which is the culmination of a year-long criminal proceeding following the November 2022 collapse of the crypto exchange FTX, Fortune reported.

See more here:

Modernas CFO on the $25 billion innovation plan to work past the post-COVID slump - Fortune